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Clinical implications of airway hyper-
responsiveness in COPD
Abstract: COPD represents one of the leading causes of mortality in the general population. 
This study aimed at evaluating the relationship between airway hyperresponsiveness (AHR) and 
COPD and its relevance for clinical practice. We performed a MEDLINE search that yielded a 
total of 1919 articles. Eligible studies were deﬁ  ned as articles that addressed speciﬁ  c aspects of 
AHR in COPD, such as prevalence, pathogenesis, or prognosis. AHR appears to be present in 
at least one out of two individuals with COPD. The occurrence of AHR in COPD is inﬂ  uenced 
by multiple mechanisms, among which impairment of factors that oppose airway narrowing 
plays an important role. The main determinants of AHR are reduction in lung function and 
smoking status. We envision a dual role of AHR: in suspected COPD, speciﬁ  c determinants 
of AHR, such as reactivity and the plateau response, may help the physician to discriminate 
COPD from asthma; in deﬁ  nite COPD, AHR may be relevant for the prognosis. Indeed, AHR 
is an independent predictor of mortality in COPD patients. Smoking cessation has been shown 
to reduce AHR. Further studies are needed to elucidate whether this functional change is as-
sociated with improvement in lung function and respiratory symptoms. 
Keywords: bronchial hyperreactivity, airway hyperresponsiveness, bronchial provocation 
tests, COPD
Introduction
The hyperresponsive state of the airways, deﬁ  ned as a condition in which the airways 
narrow too easily or too much in response to a provoking stimulus, has been historically 
associated with the asthmatic phenotype, and a body of evidence has enabled deﬁ  nition 
of airway hyperresponsiveness (AHR) as one of the cardinal features of asthma. 
However, other inﬂ  ammatory respiratory diseases, such as cystic ﬁ  brosis and COPD, 
may show an exaggerated airway response to spasmogens. The signiﬁ  cance of AHR in 
diseases other than asthma is yet to be elucidated and deserves more attention. The so-
called “Dutch hypothesis” postulates that asthma and COPD are two different aspects 
of the same disease, and that AHR predisposes to the development of both clinical 
conditions (Orie et al 1961). In this scenario, the increased airway responsiveness 
could be envisaged as a contributing factor to the development of COPD, rather than 
the consequence of this disease (Rijcken et al 1995), as proposed by the international 
guidelines for COPD (NHLBI/WHO 2001; Celli and MacNee 2004). However, the 
mechanisms underlying the relationship between AHR and COPD may not be the 
same as those between AHR and asthma.
COPD is characterized by progressive decline in lung function and impaired quality 
of life. It represents one of the leading causes of mortality in the general population, 
and its prevalence has increased dramatically in recent decades (Lopez and Murray 
1998). Despite the impact of COPD in the healthcare system, the pathophysiological 
components of the disease and the multiple clinical manifestations are not fully 
understood. In this respect, some issues need to be addressed: ﬁ  rst, the contribution International Journal of COPD 2006:1(1) 50
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of the presence (and the degree of severity) of AHR to the 
pathogenesis of COPD is not clear; second, the contribution 
of AHR to the accelerated decline in lung function and/or 
the increased mortality in COPD patients is still a matter 
of debate. Finally, if most of the clinical features and 
physiologic abnormalities of COPD are found to be linked 
to the hyperresponsive state, the potential of AHR as a target 
for COPD therapy emerges.
This article explores the relationship between AHR and 
COPD and its relevance for clinical practice with regard to 
the diagnosis, prognosis, and management of the chronic 
obstructive disease.
Methods
We performed a MEDLINE search, using the PubMed 
interface,1 to select articles that focus on AHR in patients with 
COPD. The search strategy initially included the Medical 
Subject Heading (MeSH) terms “bronchial hyperreactivity”, 
“respiratory hypersensitivity”, “bronchial provocation 
tests”, and “pulmonary disease, chronic obstructive”. 
Interestingly, “airway hyperresponsiveness” is not a MeSH 
term and is not recognized as an entry term for the MeSH 
“bronchial hyperreactivity”, which is the MeSH closest to 
the deﬁ  nition of AHR given above. To perform a more useful 
search, “free research” (ie, not restricted to the MeSH) was 
also undertaken using the following keywords: bronchial 
hyperreactivity, bronchial provocation tests, methacholine, 
histamine, adenosine, airway responsiveness, airway hyper-
responsiveness, airway hyperresponsiveness, and COPD. 
The results were restricted to articles written in English 
and studies performed in humans. The combination of the 
PubMed searches provided a total of 1919 articles (updated 
May 2005), which were subsequently checked for inclusion 
in the present review. In addition, the reference lists from 
relevant eligible studies were hand-searched. All articles 
that were identiﬁ  ed were examined for eligibility by three 
investigators independently (N Scichilone, S Battaglia, and 
A La Sala); any disagreement was discussed in a consensus 
form that included a senior investigator (V Bellia). Eligible 
studies were deﬁ  ned as the articles whose main objective 
was the evaluation of a speciﬁ  c aspect of AHR (prevalence, 
pathogenesis, prognosis) in individuals with COPD. Inclu-
sion was also restricted to studies that used methacholine, 
histamine, or adenosine as bronchoconstrictor agents in the 
bronchoprovocation tests.
Prevalence of AHR in COPD
We have previously investigated the prevalence of 
AHR in the general population, focusing on the more 
advanced ages (Scichilone, Messina, et al 2005). However, 
information regarding the prevalence of AHR in COPD 
populations is scarce because of the paucity of studies that 
speciﬁ  cally address this aspect. AHR has been measured 
in case-series studies of smokers with various degrees 
of airway obstruction; heightened airway responses to 
methacholine or histamine have been documented in the 
majority of patients (Klein and Salvaggio 1966; Benson 
1978; Ramsdell et al 1982; Bahous et al 1984; Ramsdale 
et al 1984). From these studies it can be inferred that 
AHR in COPD patients is more closely dependent on 
pre-challenge lung function and appears to be, on average, 
less severe than that recorded in subjects with asthma. To 
speciﬁ  cally establish the prevalence of AHR in individuals 
with COPD, studies with large numbers of subjects need 
to be performed. Tashkin and colleagues (1992) analyzed 
the prevalence of AHR in the context of the Lung Health 
Study. As part of this multicenter study, methacholine 
bronchoprovocation was performed in 5877 current 
cigarette smokers with borderline to moderate airﬂ  ow 
limitation. The results demonstrated that about two-thirds 
of the population had AHR, expressed as PC20 (provocative 
concentration causing 20% decrease in FEV1), which 
was signiﬁ  cantly more common in women than in men 
(85% vs 59%) and strongly related to the baseline degree 
of airﬂ  ow obstruction. 
In the context of a longitudinal study of COPD 
conducted in a small town in Northern Italy, methacholine 
bronchoprovocation was performed in 654 subjects, 50 
of whom showed symptoms consistent with chronic 
bronchitis (Cerveri et al 1988). By using a cut-off value of 
850  mg of methacholine and a PD15 (provocative dose to 
produce 15% decrease in FEV1), only nine subjects (23%) 
showed AHR. This increased to 41% when the cut-off dose 
was set at 1900  mg of methacholine. Yan and colleagues 
(1985) studied 922 adults living in Busselton, Western 
Australia. The results indicate that approximately half of 
the 59 subjects with COPD had AHR when challenged with 
histamine (PD20). When these results were compared with 
the prevalence of AHR detected in asthmatics in the same 
population, the geometric mean for PD20 was higher in 
COPD, supporting the concept of less severe AHR in this International Journal of COPD 2006:1(1) 51
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condition. Interestingly, there was a positive correlation 
between FEV1/FVC and PD20 values in subjects with 
COPD but not in those with asthma, thus conﬁ  rming that 
in COPD AHR is dependent on the initial airway caliber. 
In this regard, the geometric factor (pre-challenge lung 
function) plays a controversial role in determining the 
degree of AHR (McParland et al 2003). As discussed below, 
the structural changes that occur in the airway walls could 
have beneﬁ  cial effects on airway reactivity. In the study 
by Yan and co-workers (1985), the lack of a signiﬁ  cant 
correlation in the asthmatic population could be simply 
attributed to a statistical weakness, or alternatively it could 
unveil the “protective” role of ﬁ  xed bronchial obstruction.
The results on AHR prevalence in COPD from these 
studies are not superimposable. It seems conceivable that the 
discrepancy in terms of prevalence depends on the differences 
between studies. First, and probably most important, the 
different size of the sample populations limits comparison 
of the outcomes. Also, the different spasmogen used and 
the higher proportions of current smokers and women in 
the Lung Health Study may have contributed to the different 
outcomes. Smoking status strongly affects the occurrence 
of AHR. It is, therefore, not surprising that the results of 
the Lung Health Study show a higher prevalence of AHR. 
Similarly, the higher proportion of females could account 
for the discrepancy in AHR prevalence, in that women have 
smaller lung volumes and consequently smaller airway 
caliber, which in turn increases AHR, as demonstrated by 
Bakke and co-workers (1991). 
In conclusion, from the few available studies we can 
assume that at least one out of two COPD patients has some 
degree of AHR. In this context, major questions are raised 
and pose a challenge for future research: why do only a 
proportion of individuals with COPD show AHR, and what 
prevents AHR from occurring in the non-hyperresponsive 
patients with COPD?
Clinical relevance of AHR in COPD
In the diagnosis of asthma, the importance of AHR is well 
recognized, especially in cases in which baseline lung function 
is within the normal range. In addition, AHR can be important 
in determining the optimal inhaled steroid dosage, because 
therapy based only on symptoms and spirometry may be 
inadequate (Sont et al 1999). Furthermore, in asthma the 
degree of AHR may add useful information for the prognosis, 
in that the exacerbation rate appears to be highest in patients 
with severe hyperresponsiveness (Sont et al 1999). In contrast, 
the clinical relevance of AHR in COPD is less well deﬁ  ned, 
mainly because the bronchoprovocation test is often not 
ordered or not performed in individuals with COPD or in 
those with low lung function. Theoretically, the presence of 
AHR, or its degree of severity, can be important for diagnosis, 
prognosis, and/or therapy decisions. In our opinion, the 
evaluation of AHR could be indicated in two clinical settings, 
the ﬁ  rst being represented by conditions in which the diagnosis 
of COPD and asthma may be confused. This is particularly 
true for mild forms of COPD, in which lung function is 
only mildly impaired and respiratory symptoms may not 
be fully descriptive of COPD; in this case, the diagnosis 
of COPD may be challenging. On the other hand, some 
asthmatic patients are characterized by airway obstruction 
that is not reversible and may pose diagnostic issues. In this 
regard, Fabbri and colleagues (2003), by investigating the 
differences in patients with ﬁ  xed airﬂ  ow limitation due to 
asthma or COPD, concluded that AHR (PD20 methacholine) 
does not distinguish between the two clinical entities. The 
task is, therefore, to detect speciﬁ  c characteristics of AHR in 
COPD that could enable the physician to solve the diagnostic 
dilemma. The second scenario includes individuals with a 
deﬁ  nite diagnosis of COPD, in whom the bronchoprovocation 
challenge could provide potential advantages in terms of 
treatment and prognosis. 
AHR in suspected COPD
It is worth noting that the presentation of COPD can be 
heterogeneous and it can often overlap that of asthma. 
The heterogeneity of the clinical presentation implies that 
patients with COPD may show some characteristics that 
are more frequently observed in asthmatics. There are 
three possible reasons for this: real non-classic presentation 
of COPD, simultaneous presence of the two diseases, or 
erroneous diagnosis. In clinical settings, cases of asthma 
can be misdiagnosed as COPD, especially in the elderly and 
in individuals with disability (Bellia et al 2003). In clinical 
practice, the two conditions can coexist and this presentation 
is referred to as “asthmatic bronchitis” or “wheezy bron-
chitis”. Unfortunately, little is known about this condition, 
mainly because most studies exclude these patients to avoid 
confounding factors. Data from two epidemiological surveys 
in rural and urban areas of Italy demonstrated that up to 30% International Journal of COPD 2006:1(1) 52
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of patients with COPD had asthma, and up to 14% of patients 
with asthma had COPD (Viegi et al 2004). Further studies 
are needed to establish the role of AHR in the prognosis 
and management of asthmatic bronchitis and to evaluate the 
therapeutic response in this condition. 
In the case of suspected COPD, a positive broncho- 
provocation challenge does not help to differentiate COPD 
from asthma, since, as discussed above, a degree of AHR 
is present in a large proportion of patients with COPD. 
However, given the high sensitivity and negative predictive 
value of the methacholine bronchoprovocation in asthma 
(ATS 2000), a negative test would rather favor the diagnosis 
of COPD. Studies in which agents other than methacholine 
have been used may help to distinguish COPD from asthma 
(Postma and Kerstjens 1998). For instance, despite showing 
a similar degree of bronchoconstriction to methacholine, 
smokers with chronic bronchitis and COPD generally do not 
show response to acetaldehyde (Sanchez-Toril et al 2000). 
Therefore, this test has been proposed as more speciﬁ  c than 
methacholine (95% vs 24%). In addition, COPD smokers 
show greater response to adenosine 5′-monophosphate 
(AMP) than ex-smokers (Oosterhoff et al 1993), and AHR 
to AMP is associated with a higher number of sputum 
eosinophils (Rutgers et al 2000). Therefore, the role of 
inﬂ  ammation in the pathogenesis of AHR in COPD may 
be further explored by using this test. Perhaps AMP may 
better differentiate COPD from asthma and can contribute 
to selecting subgroups of COPD subjects who will beneﬁ  t 
from antiinﬂ  ammatory therapy.
Since the bronchoprovocation test cannot accurately 
distinguish between asthma and COPD, inclusion of the test 
in the diagnostic approach should not be routinely recom-
mended. In this context, the advantage of assessing AHR in 
suspected cases of COPD could be provided by more speciﬁ  c 
aspects of AHR, such as exaggerated airway narrowing. Many 
investigators have clearly demonstrated that the outcome of 
the bronchoprovocation test depends on the pre-challenge 
lung function (Ryan et al 1982; Ramsdale et al 1984; Verma 
et al 1988; Sterk and Bel 1989). In other words, the lower 
the baseline FEV1, the higher the magnitude of AHR. This 
is true both in asthma and in COPD (Brand et al 1991) and 
can be purely attributed to geometric mechanisms. Using a 
mathematical model, Moreno and colleagues (1986) dem-
onstrated that, for a given degree of airway smooth muscle 
(ASM) shortening, increased thickness of airway wall ampli-
ﬁ  es airway narrowing. Thickening of the airway wall can also 
uncouple the airways from the surrounding parenchyma, thus 
reducing the tethering forces that oppose airway narrowing. 
As a consequence, the assessment of AHR in individuals 
with low FEV1 (<70% of predicted value) has apparently 
no usefulness. However, structural changes of the asthmatic 
airway walls may have a protective effect against narrow-
ing, in that the elastic load provided by collagen deposition 
and the folding of the ASM as it contracts may limit further 
shortening (Meiss 1999; McParland et al 2003). Therefore, 
the causes of reduction in airway caliber and the manifesta-
tions of AHR may differ between the two clinical conditions, 
as discussed below.
Airway narrowing in response to spasmogens is 
the result of opposing forces, ie, those related to ASM 
shortening and the distending forces applied to the outer 
airway wall surface by the alveolar septa. In the context of 
destroyed lung parenchyma, the load that counteracts the 
shortening of ASM is depressed and this favors maximal 
airway narrowing. In this respect, one should focus on the 
reactivity (the slope of the dose-response curve), which 
in COPD has been demonstrated to depend on the reduc-
tion of FEV1 (Verhoeven et al 2000) and on airway wall 
thickness (Corsico et al 2003). The maximal response on 
the dose-response curve describes a condition of increased 
risk of severe bronchoconstriction. Koh and colleagues 
(2002) showed that the elevated maximal response to 
methacholine (ie, the lack of plateau), but not the increased 
sensitivity to the stimulus (ie, the threshold dose), predicts 
the risk of developing asthma in individuals with allergic 
rhinitis. The plateau value, which is a measure of exces-
sive maximal narrowing, is mainly determined by the lung 
elastic forces that oppose ASM contraction. A plateau 
response is usually not attained in asthma, especially 
in more severe cases (Woolcock et al 1984) because of 
inﬂ  ammatory changes that uncouple the parenchyma and 
the airways. In COPD, the lack of a plateau is attributed 
to the structural changes in the lung that cause a reduction 
in the elastic recoil, thus impairing the tethering forces ap-
plied to the outer airway wall (Colebatch et al 1973). The 
study performed by Cheung et al (1997) provides a unique 
model of the relationship between the characteristics of 
AHR and the loss of elastic recoil. In this study, the authors 
recruited subjects with α1-antitrypsin deﬁ  ciency and no 
current history of smoking, and found a close relationship 
between the degree of parenchymal destruction and the 
maximal airway narrowing. On the other hand, plateaus 
in the dose-response curve have been documented in some 
individuals with COPD (Verhoeven et al 2000). It can, 
however, be theorized that, given the structural alterations 
of the lung parenchyma, higher reactivity is likely to occur International Journal of COPD 2006:1(1) 53
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in COPD subjects. From the above observations, it can be 
argued that various components of airway responsiveness 
need to be combined in order to distinguish asthma from 
COPD. This would also shed light on the pathogenesis of 
AHR in chronic respiratory disorders, in that sensitivity is 
considered to be affected by pre-junctional mechanisms, 
such as inﬂ  ammation, whereas the plateau value is mainly 
inﬂ  uenced by post-junctional factors, such as lung elastic 
recoil.
How can this information be translated into clinical 
practice? The level of expertise required to measure the 
above-described variables precludes extensive applica-
bility of the bronchoprovocation test. To overcome this 
limitation, assessment of the fall in FVC at the level of 
PC20 could provide an indirect measure of excessive airway 
narrowing and should be encouraged among physicians 
who are responsible for the management of COPD. Since 
elastic recoil is considered a limiting factor for the maximum 
decrease in airway caliber during bronchoconstriction (Ding 
et al 1987), structural alterations in lung elasticity may 
result in enhanced bronchoconstriction. In this context, the 
senile lung is characterized by structural and functional 
alterations (Verbeken et al 1992a, 1992b) that could favor 
airway narrowing and increased airway responsiveness. 
The results from an analysis conducted on studies speciﬁ  -
cally addressing the relationship between age and AHR are 
in favor of a positive correlation between these two factors 
(Scichilone, Messina, et al 2005). This is also suggested by 
the observation that, despite comparable pulmonary function 
and PC20 FEV1, elderly patients with asthma show higher 
AHR than young asthmatics, when expressed by metha-
choline-induced changes in FVC (Cuttitta et al 2001). This 
evidence implies that age-associated structural alterations in 
elderly asthmatic patients contribute to determining a higher 
risk of early airway closure. As suggested by Macklem 
(1989), this phenomenon is ampliﬁ  ed in COPD patients, in 
whom parenchymal destruction occurs.
AHR in deﬁ  nite COPD
In cases in which the diagnosis of COPD is already estab-
lished, or in individuals at risk of developing more severe 
COPD (smokers and stage 0 in the GOLD classiﬁ  cation) 
(NHLBI/WHO 2001), the presence of AHR may be important 
for the prognosis. The most important clinical question is 
whether AHR can be an independent predictor of mortality. 
To our knowledge, only one study has addressed the associa-
tion between AHR and COPD mortality on a longitudinal 
basis (Hospers et al 2000). The authors presented ﬁ  ndings 
from the Dutch epidemiological surveys of Vlagtwedde, 
Vlardingen, and Meppel and analyzed 526 deaths. After 
24-year follow-up, they identiﬁ  ed 60 patients who died 
with COPD as the primary or secondary cause of death. The 
study showed that the severity of AHR was associated with 
higher risk of mortality. These results corroborate the role of 
AHR as a predictor of mortality, although these observations 
were, to some extent, criticized (Vestbo and Hansen 2001). 
Indeed, it has been hypothesized that the “AHR factor” could 
be reduced to an insigniﬁ  cant level by already established 
predictors, such as lung function (Vestbo and Hansen 2001). 
In the Hospers et al study (2000), there was a correction for 
different subsets of baseline FEV1 (>100%, 80–100%, and 
<80% of predicted values). However, the category of <80% 
of predicted seems too wide and could be insufﬁ  cient to 
control for this factor. Moreover, the contribution of smoking 
status and the presence of asthma should probably have been 
evaluated in more detail. 
Is the assessment of AHR in patients with COPD impor-
tant for the management of the disease? It is known that asth-
matic patients show improvement in AHR after inhaled ster-
oid therapy as assessed by either direct (Overbeek et al 1996) 
or indirect (van den Berge et al 2001) stimuli. Conversely, 
conﬂ  icting evidence has been reported in COPD. One large 
longitudinal randomized, placebo-controlled clinical trial 
on COPD (559 cases vs 557 controls) has demonstrated 
that inhaled corticosteroids improved AHR after long-term 
treatment (Lung Health Study Research Group 2000). The 
results showed that, at 9 and 33 months, the triamcinolone 
group had less reactivity in response to methacholine than 
the placebo group. Despite this improvement, pulmonary 
function decline was not inﬂ  uenced. In contrast, other authors 
reported that inhaled corticosteroid treatment had no effect on 
AHR. A randomized, placebo-controlled, double-blind trial 
in 59 nonasthmatic COPD patients who completed a 2-year 
follow-up demonstrated that inhaled beclomethasone did not 
change AHR to histamine (Weir et al 1999). Verhoeven et al 
(2002) demonstrated that 6 months of inhaled corticosteroids 
(ﬂ  uticasone) did not modify PC20 or other indices of AHR, 
such as the slope of the dose-response curve, the plateau value 
(maximal bronchoconstriction), or the concentration of the 
stimulus causing 50% of maximal bronchoconstriction. These 
data conﬁ  rm previous results showing that, in smokers with 
chronic bronchitis or COPD, treatment with inhaled corticos-
teroids (budesonide) for 6–12 weeks did not improve AHR 
(PC20 or PD20 histamine) to any clinically signiﬁ  cant extent 
(Engel et al 1989; Auffarth et al 1991; Watson et al 1992; Weir 
and Burge 1993). Several factors may be advocated to explain International Journal of COPD 2006:1(1) 54
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these differences. The Lung Health Study (Lung Health Study 
Research Group 2000) accounts for a total of 1116 patients 
and has more statistical power in detecting small differences 
than the other trials, which consisted of groups of 14 to 
105 subjects (Engel et al 1989; Auffarth et al 1991; Watson 
et al 1992; Weir and Burge 1993; Weir et al 1999; Verhoeven 
et al 2002). Six months (Verhoeven et al 2002) and 2 years 
(Weir et al 1999) of treatment should be a suitable length 
of time to evaluate modiﬁ  cation in the histamine challenge 
test. It is well known that in asthma a period of 4 weeks 
is needed to detect any beneﬁ  cial effect of corticosteroids 
on AHR assessed by methacholine (Prosperini et al 2002), 
whereas only 72 hours is required to improve histamine 
responsiveness (Sovijarvi et al 2003). 
Finally, the difference in bronchoconstrictor agents used 
seems of minor importance, because both methacholine 
and histamine act as direct stimuli. It is interesting to 
note that corticosteroids do not reduce AHR, even when 
indirect stimuli are used. It has been demonstrated 
that AHR to AMP in smoker and non-smoker COPD 
subjects is signiﬁ  cantly lower than in smoker healthy 
controls (Oosterhoff et al 1993). Treatment with inhaled 
corticosteroids did not signiﬁ  cantly change PC20 AMP 
(Rutgers et al 1998). In the active treatment group of 
22 non-atopic current smokers with COPD, who were 
equally reactive to AMP and methacholine under baseline 
conditions, 6-week therapy with inhaled budesonide 
did not improve AHR to AMP, and the sensitivity to the 
indirect stimulus produced by AMP was not greater than 
that of methacholine (Rutgers et al 1998). This may be 
explained by various hypotheses: (1) the reduction in mast 
cell numbers in the airway wall mucosa observed after 
treatment with inhaled corticosteroids (Hattotuwa et al 
2002) is too small to result in changes in AHR to AMP in 
patients with COPD; (2) mast cells are not greatly activated 
and/or involved in the inﬂ  ammatory process of COPD.
Mechanisms of AHR in COPD
AHR in COPD may occur through multiple mechanisms, 
which are summarized in Figure 1. Although the contribution 
of each factor to the development of increased airway response 
to stimuli has been a subject of extensive investigation, the 
interaction between them remains largely disputed. In 
particular, recent evidence from in vivo and mathematical 
modeling revives the theory of cigarette smoking as the 
promoting factor of the cascade of events which, ultimately, 
induce AHR. On the other hand, evidence from transgenic 
technology and genetic screening provides support for genetic 
determinants of AHR, although, to our knowledge, candidate 
genes in COPD have not been replicated or performed in 
sufﬁ  ciently powered populations. 
Airway smooth muscle
Since the primary mechanism of airway obstruction is 
contraction of ASM, the behavior of this tissue should 
primarily be assessed. Abnormal ASM contraction can be 
attributed to increased velocity of shortening, or simply to 
the increased amount of muscle, although increased force 
generation as assessed in vitro does not necessarily translate 
into in vivo ASM shortening. The possibility should also 
be taken into account that ASM has a “synthetic” function, 
producing and/or releasing factors that promote inﬂ  ammation 
and increase contractility (Howarth et al 2004). The evaluation 
of ASM contractility from COPD subjects has yielded 
conﬂ  icting results (Taylor et al 1985; De Jongste et al 1987; 
Black 1991). De Jongste and colleagues (1987) showed that 
isolated bronchioles from COPD subjects exhibited greater 
maximal isometric forces than that recorded from subjects 
without COPD. These observations have been recently 
conﬁ  rmed by Opazo-Saez and co-workers (2000), suggesting 
that, together with loss of elastic recoil and remodeling of 
small airways (see below), altered smooth muscle function 
plays a role in the development of AHR. Alternatively, smooth 
muscle may contract normally, but the increase in its mass, 
per se or by increasing the thickening of the airway wall, 
leads to excessive airway narrowing. ASM content increases 
signiﬁ  cantly in the small airways in COPD (Jeffery 2001) 
and contributes to the overall thickness of the airway wall. 
Computational modeling of the bronchial tree has revealed 
Figure 1 Schematic of the potential mechanisms underlying the relationship 
between AHR and COPD. Abbreviations: AHR, airway hyperresponsiveness; 
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bronchodilatory effect decreases with increasing severity of 
asthma (Scichilone et al 2002) and is abolished in subjects 
with COPD (Scichilone et al 2004b). The mechanisms 
through which a deep inspiratory maneuver acts are mediated 
by the tethering forces that are applied to the airway walls, 
and any factor affecting the interdependence between airways 
and the surrounding parenchyma can blunt the ability 
of DI to further distend airways (Figure 2). At least two 
conditions could result in the loss of lung inﬂ  ation-induced 
bronchodilation. On one hand, increased thickness of the 
airway wall, such as that observed in the more severe stages 
of asthma, could induce greater stiffness of airways, which 
in turn would oppose airway distension (Figure 2[1]). On 
the other hand, reduction of elastic recoil could diminish 
the radial traction of the airway walls, allowing for loss of 
supporting tissue for peripheral airways with ease of airway 
closure (Figure 2[2]) (Cheung et al 1997). This would 
explain, for example, why bronchodilation by DI appears to 
be essentially absent in individuals with structural changes 
in lung parenchyma, such as emphysema (Scichilone et al 
2004b). Recent observations from our group (Scichilone, 
Bruno, et al 2005) indicate that the attenuation of the 
bronchodilatory effect of DI in COPD is proportional to the 
that increased thickness of the airways augments reactivity, 
rather than sensitivity. By dissecting the different components 
of the airways, Lambert and colleagues (1993) and Tiddens 
and colleagues (1999) demonstrated that the ASM content is 
the most important factor responsible for the bronchoconstrictive 
response to stimuli in COPD. Against the airway thickening 
hypothesis is the evidence that thicker airways may have 
a protective role against broncho- constrictors (Milanese 
et al 2001; Niimi et al 2003). Niimi and colleagues (2003) 
showed that in asthmatics, thickened airway walls, as assessed 
by high-resolution computed tomography (HRCT) scans, 
inversely correlated with airway reactivity. The thickening of 
airway smooth muscle is also determined by accumulation of 
matrix which opposes airway contraction. As Pare (2003) has 
recently pointed out, an increased amount of muscle may not 
mean greater contractile capacity. The possibility should also 
be considered that, in COPD, ASM reaches a “frozen” state 
(Fredberg 2000), in which actin and myosin ﬁ  laments are tightly 
bound. According to this theory (Fredberg et al 1997; Fredberg 
2000), the frozen state is attained when the smooth muscle is 
not subjected to periodic stretches, such as in the condition of 
reduced excursions that are observed in the airways in COPD. 
This phenomenon would lead to increased responsiveness, as 
inferred by a pivotal study by Skloot and colleagues (1995), 
who demonstrated that prohibiting deep inspiratory maneuvers 
in healthy individuals produced a reaction to methacholine of 
the same magnitude as that in asthmatics. 
Deep inspiration
Deep inspiratory maneuvers have been demonstrated to 
exert beneﬁ  cial effects on the airways of healthy individuals 
(Pellegrino et al 1996, 1998; King et al 1999; Kapsali et 
al 2000; Scichilone et al 2000, 2004a; Brown et al 2001; 
Scichilone, Pyrgos, et al 2001; Sundblad and Larsson 2002; 
Jackson et al 2004; Salerno et al 2005). It has been widely 
demonstrated that deep inspirations (DI) are able to revert 
bronchial obstruction that has been experimentally provoked 
(Pellegrino et al 1996, 1998; King et al 1999; Scichilone 
et al 2000, 2004a; Brown et al 2001; Scichilone, Pyrgos, 
et al 2001; Sundblad and Larsson 2002; Jackson et al 
2004). For this reason, a DI is considered among the most 
potent bronchodilators. Using single-dose methacholine 
bronchoprovocation, we have established the methodology 
to measure the bronchodilatory effect of DI (Scichilone 
et al 2000; Scichilone, Permutt, et al 2001), which allows 
us to explore the phenomenon of airway distensibility and 




Figure 2 Schematic of the interdependence between the airway and the 
surrounding parenchyma, showing the opposing forces, ie, those distending the 
airway and those causing narrowing. The former are sustained by increased lung 
volumes and mediated by the connective tissue; the latter are induced by airway 
smooth muscle contraction. The bronchodilatory effect of deep inspiration, which 
is mediated by the tethering forces that are applied to the airway walls, can be 
affected by two mechanisms: thickness of the airway wall due to remodeling 
changes (1), or structural damage to the parenchymal tissue (2).International Journal of COPD 2006:1(1) 56
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parenchymal damage, as assessed by the content of destroyed 
alveolar septa. We propose that the different magnitudes of 
DI-induced bronchodilation could, to some extent, account 
for the variance in the degree of AHR. In other words, 
whereas in healthy individuals the broncho-dilatory effect 
of DI is present and manages to adequately counteract 
airway tone so that bronchoconstriction does not take place, 
in patients with COPD, the bronchodilatory effect of DI is 
blunted and may not be sufﬁ  cient to balance the additional 
airway tone induced by an extrinsic stimulus, thus affecting 
the magnitude of induced bronchoconstriction.
In addition to the bronchodilatory effect, lung inﬂ  ation 
exerts a bronchoprotective role in healthy individuals; ie, a 
series of DI taken before inhalation of the spasmogen is able 
to prevent airways from narrowing. We have demonstrated 
that asthmatic and rhinitic subjects with AHR show 
impairment in bronchoprotection induced by DI (Scichilone, 
Permutt, et al 2001), irrespective of respiratory symptoms. 
Therefore, reduced bronchoprotection by DI could result 
from very early inﬂ  ammation-induced functional or structural 
alterations in the airways. Whether this applies to COPD 
is yet to be proven. To date, the effects of DI on AHR in 
COPD patients have not been speciﬁ  cally addressed. We 
suggest that lung inﬂ  ation is responsible for maintenance of 
airway patency in healthy humans, and that the loss of this 
function in COPD contributes to the occurrence of AHR. We 
recently showed that DI-induced bronchoprotection can be 
restored by inhaled glucocorticosteroids only in asthmatics 
with mild hyperresponsiveness (Scichilone, Permutt, et al 
2005). To date, we do not know whether the lack of DI-
induced bronchoprotection is predictive of the response to 
pharmacological and nonpharmacological therapy in COPD.
Inﬂ  ammation
In asthma, AHR has been associated with airway inﬂ  ammation 
(NHLBI/WHO 2001). The same paradigm could be applied 
in COPD, although the nature of inflammation differs. 
Postma et al (1988) demonstrated, in COPD subjects, a 
close association between AHR to histamine and superoxide 
anion production from peripheral leukocytes. In assessing 
the inﬂ  ammatory aspect of the relationship between AHR 
and COPD, the inﬂ  ammation-induced abnormalities that 
occur in the parenchymal compartment must be discussed. 
In COPD, the elastolytic destruction of the parenchyma and 
the consequent loss of elastic recoil decrease the support to 
the smaller airways, thus increasing airway collapsibility 
and early closure. This can be enhanced by the structural 
changes that occur in the small airways (Jeffery 2001). 
On the other hand, the asthmatic inﬂ  ammation is conﬁ  ned 
to the airways, with little or no effect on the surrounding 
parenchyma; therefore, the increase in airway resistance 
is predominantly attributed to remodeling changes of the 
airway walls. The differences in small airway pathology 
between asthma and COPD may support this hypothesis. It 
has been demonstrated that the small airways from asthmatic 
subjects contain a signiﬁ  cantly greater density of CD45+ 
lymphocytes in the outer adventitial region as opposed to 
the inner submucosal region (Haley et al 1998). In COPD 
subjects, the opposite phenomenon occurs, in that the density 
of CD45+ lymphocytes is higher in the inner than in the 
outer wall region (Saetta et al 2000). These observations are 
consistent with mathematical models examining the role of 
submucosal thickening, adventitial thickening, and increase 
in smooth muscle mass as contributors to the AHR of asthma 
and COPD (Lambert et al 1993). Using a mathematical 
model, Lambert and colleagues (1993) postulated that the 
increase in muscle mass appears to be the most important 
feature accounting for AHR. However, the increases in the 
adventitial and the submucosal areas also play an important 
role (Lambert et al 1993). Although this computer-generated 
model needs to be conﬁ  rmed, it is conceivable that in asthma 
the increased cellular density in the adventitia would promote 
airway constriction by reducing the effectiveness of airway to 
parenchyma interdependence, whereas the increased cellular 
density observed in the submucosa of individuals with COPD 
would promote airway constriction by amplifying the effect 
of ASM shortening (Lambert et al 1993; Saetta et al 2000).
Allergy
It has been postulated that allergic or immune factors play a 
role in modulating AHR in COPD. In non-allergic (negative 
skin tests) patients with COPD, higher serum total IgE levels 
were independently associated with a lower PC20 histamine 
at baseline (Renkema et al 1998). This observation has 
been conﬁ  rmed by Mitsunobu and colleagues (2001), who 
demonstrated that AHR to methacholine is enhanced by the 
presence of speciﬁ  c IgE antibodies against inhalant allergens 
in patients with COPD. Data from a 2-year follow-up study 
showed that higher initial serum total IgE levels were as-
sociated with a slower annual decline of PC20, regardless of 
treatment and pre-challenge FEV1 (Renkema et al 1998). The 
observation that the initial serum total IgE level predicts a 
more favorable course with regard to annual decline of PC20 
histamine could be in line with the assumption that COPD International Journal of COPD 2006:1(1) 57
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patients with features of asthma have a better prognosis than 
those with “pure emphysema” conditions. Thus, one would 
have expected that increased total IgE would indicate the 
presence of a “responsive group” to inhaled corticoster-
oids. However, regardless of total IgE levels, corticosteroid 
therapy did not inﬂ  uence changes in PC20 over time (Dow 
1998; Renkema et al 1998). Perhaps one explanation is that 
elevated IgE levels do not always imply the presence of 
atopic asthma; for instance, they could be related to tobacco 
smoking (Dow 1998). 
Smoking status 
Since cigarette smoking is the greatest independent risk factor for 
the development of COPD, studies on the role of AHR in COPD 
have concentrated on the effect of smoke. If a relationship does 
exist, it can be expected that smoking cessation strategies would 
improve AHR in COPD. Airway response to cigarette smoking 
shows a dose-dependent relationship with the consumption of 
cigarettes (Jensen et al 1998). The effect of smoking on AHR 
is mediated by inﬂ  ammatory or neurogenic mechanisms, which 
are intertwined with the effect on lung geometry. Smoking 
stimulates nerve endings in the airway walls, with consequent 
edema, mucus hypersecretion, and recruitment of inﬂ  ammatory 
cells. Willemse et al (2004) recently demonstrated that 1-year 
smoking cessation led to improvement in AHR in individuals 
with COPD. This may result from reduced stimulation of the 
irritant receptors, reduction in mucus secretion, or changes 
in the inﬂ  ammatory cells. The results from the Lung Health 
Study also showed an increase in AHR over a 5-year period 
in COPD subjects who continued to smoke, but not in those 
who quit (Wise et al 2003). Since ex-smokers also improved, 
or stabilized, their lung function, it cannot be excluded that 
the beneﬁ  t of smoking cessation was merely due to geometric 
changes of the airways.
Genetic determinants
It is generally assumed that an interaction between genetic 
determinants and environmental factors initiates the develop-
ment of COPD. Several candidate genes have been identi-
ﬁ  ed as related to COPD, but some of them have not been 
conﬁ  rmed or replicated in different populations. Given the 
role of AHR in the development and the course of COPD, 
the genetic predisposition to AHR in these individuals should 
also be assessed. Genetic susceptibility to AHR has been 
largely analyzed in asthma, and it has been demonstrated 
to be coinherited with genetic markers on chromosome 
5q31–q33 (Postma et al 1995). Coding genes for interleukin 
(IL)-4 and IL-13, which are implicated in the development 
of AHR, are also located in chromosome 5q31. Hegab and 
colleagues (2004) recently investigated polymorphisms 
within these genes in two different populations consisting of 
Japanese (88 COPD and 61 healthy controls) and Egyptian 
(106 COPD and 72 healthy controls) subjects, and they were 
able to demonstrate signiﬁ  cant group-speciﬁ  c differences 
between COPD individuals and healthy controls. In conclu-
sion, the few studies performed do support a genetic basis 
for the development of AHR in COPD, but the precise role 
of genetic determinants in this condition is still uncertain.
Conclusions
AHR may be envisaged as an important component of COPD. 
In the clinical setting, the importance of assessing AHR in COPD 
individuals is still underestimated, mainly because physicians 
tend to avoid bronchoprovocation challenges in individuals with 
COPD or with low lung function. In cases of suspected COPD, 
speciﬁ  c determinants of the dose-response curve might provide 
additional information to the diagnostic approach. In the context 
of COPD, AHR has been demonstrated to be a predictor of 
mortality; thus, reduction in the severity of AHR by smoking 
cessation strategies could potentially inﬂ  uence the natural his-
tory of COPD. Understanding of the pathophysiology of AHR 
in COPD may contribute to better characterization of patients 
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